|Videos|March 30, 2022

How to implement InterStim in your practice

Author(s)Urology Times staff

“I think the main thing is placement of the neural probe on the first go around,” says David W. Law, DO.

In this video, David W. Law, DO, discusses InterStim, a sacral nerve modulation therapy for treatment of overactive bladder, and gives advice on how to best use it in practice. Law is the chief of surgery at Oakwood Southshore Medical Center in Trenton, Michigan, and clinical professor in the department of urology at the Michigan State University Medical School in East Lansing.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Content

Narmina Khanmammadova, MD, discusses findings on pelvic floor therapy before HoLEP

ByNarmina Khanmammadova, MD

August 12th 2026

Optimizing care for men with overactive bladder, with Keith Xavier, MD

ByKeith Xavier, MD, URPS

August 6th 2026

FDA clears Revi Extend implant for urgency urinary incontinence

ByHannah Clarke

August 5th 2026

Sender Herschorn, BSc, MDCM, FRCSC, on vibegron efficacy in older men with OAB and BPH

BySender Herschorn, BSc, MDCM, FRCSC

July 8th 2026

Retrospective study suggests differences in OAB therapy persistence among older adults

ByUnwanaobong Nseyo, MD, MHS

June 20th 2026

Latest CME

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Burst CME™: Recognizing Lupus Nephritis—From Timely Diagnosis to Appreciating the Underlying Mechanisms of Disease

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Burst CME™: Staying Informed and Up-To-Date on the Treatment of Lupus Nephritis

Michelle Petri, MD, MPH; Shivani Garg, MD, PhD

Trending on Urology Times

The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD

CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom

Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy

FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care